Khiron (TSXV: KHRN) enters key development phase for selling products in Latin America
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) reports it has initiated pre-clinical medical cannabis studies with the Universidad de la República of Uruguay and Institut Pasteur de Montevideo.
These studies, which have been approved by the Instituto de Regulación y Control del Cannabis (IRCCA) - the Regulatory Cannabis State Authority of Uruguay will focus on the effects of three licensed Khiron strains targeting inflammation, oxidative and nervous system disorders. This is a key development phase as KHRN moves towards medical registration and sale of its products in Latin America and for export worldwide. Martha Edith Oyuela, Khiron Health Vice President, comments, "As we approach our first medical product sales in Colombia this quarter, these studies improve our medical product pipeline in Latin America and around the world, and help us integrate a care model focused on patients who require the management of different pathologies in which medical cannabis can offer a therapeutic alternative."
The illegal status of cannabis for decades has left the rigorous scientific testing and analysis sorely lacking. This study will examine the impact of three Khiron licensed cannabis strains on inflammation, oxidative and nervous system disorders. If the results are positive, it will enable KHRN to inform potential patients who can make better informed decisions.